vs
Side-by-side financial comparison of Elme Communities (ELME) and RxSight, Inc. (RXST). Click either name above to swap in a different company.
Elme Communities is the larger business by last-quarter revenue ($62.1M vs $32.6M, roughly 1.9× RxSight, Inc.). RxSight, Inc. runs the higher net margin — -28.1% vs -198.9%, a 170.8% gap on every dollar of revenue. On growth, Elme Communities posted the faster year-over-year revenue change (1.7% vs -18.9%). Elme Communities produced more free cash flow last quarter ($7.2M vs $-2.3M). Over the past eight quarters, RxSight, Inc.'s revenue compounded faster (5.1% CAGR vs 2.7%).
Elme Communities is a publicly traded U.S. real estate investment trust that primarily owns, operates and develops high-quality multifamily residential communities. It focuses on key growth markets across the U.S. Mid-Atlantic and Southeast, offering affordable to mid-tier housing options for diverse renter groups.
RxSight, Inc. is a medical technology company focused on developing and commercializing innovative intraocular lens solutions for patients undergoing cataract and refractive lens exchange procedures. Its flagship Light Adjustable Lens allows post-surgery power adjustment via a dedicated light delivery device, serving global ophthalmology care markets to improve post-operative visual outcomes for patients.
ELME vs RXST — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $62.1M | $32.6M |
| Net Profit | $-123.5M | $-9.2M |
| Gross Margin | 61.1% | 77.5% |
| Operating Margin | -183.3% | -34.8% |
| Net Margin | -198.9% | -28.1% |
| Revenue YoY | 1.7% | -18.9% |
| Net Profit YoY | -4058.7% | -54.1% |
| EPS (diluted) | $-1.40 | $-0.22 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $32.6M | ||
| Q3 25 | $62.1M | $30.3M | ||
| Q2 25 | $62.1M | $33.6M | ||
| Q1 25 | $61.5M | $37.9M | ||
| Q4 24 | $61.3M | $40.2M | ||
| Q3 24 | $61.1M | $35.3M | ||
| Q2 24 | $60.1M | $34.9M | ||
| Q1 24 | $59.5M | $29.5M |
| Q4 25 | — | $-9.2M | ||
| Q3 25 | $-123.5M | $-9.8M | ||
| Q2 25 | $-3.6M | $-11.8M | ||
| Q1 25 | $-4.7M | $-8.2M | ||
| Q4 24 | $-3.0M | $-5.9M | ||
| Q3 24 | $-3.0M | $-6.3M | ||
| Q2 24 | $-3.5M | $-6.1M | ||
| Q1 24 | $-3.6M | $-9.1M |
| Q4 25 | — | 77.5% | ||
| Q3 25 | 61.1% | 79.9% | ||
| Q2 25 | 63.5% | 74.9% | ||
| Q1 25 | 64.2% | 74.8% | ||
| Q4 24 | 62.9% | 71.6% | ||
| Q3 24 | 63.5% | 71.4% | ||
| Q2 24 | 63.4% | 69.5% | ||
| Q1 24 | 63.5% | 70.1% |
| Q4 25 | — | -34.8% | ||
| Q3 25 | -183.3% | -40.1% | ||
| Q2 25 | 9.6% | -41.6% | ||
| Q1 25 | 7.8% | -28.2% | ||
| Q4 24 | 10.4% | -21.5% | ||
| Q3 24 | 11.0% | -26.1% | ||
| Q2 24 | 9.8% | -23.9% | ||
| Q1 24 | 7.5% | -36.2% |
| Q4 25 | — | -28.1% | ||
| Q3 25 | -198.9% | -32.4% | ||
| Q2 25 | -5.7% | -35.0% | ||
| Q1 25 | -7.6% | -21.6% | ||
| Q4 24 | -4.9% | -14.8% | ||
| Q3 24 | -4.9% | -17.9% | ||
| Q2 24 | -5.8% | -17.4% | ||
| Q1 24 | -6.1% | -30.8% |
| Q4 25 | — | $-0.22 | ||
| Q3 25 | $-1.40 | $-0.24 | ||
| Q2 25 | $-0.04 | $-0.29 | ||
| Q1 25 | $-0.05 | $-0.20 | ||
| Q4 24 | $-0.04 | $-0.14 | ||
| Q3 24 | $-0.03 | $-0.16 | ||
| Q2 24 | $-0.04 | $-0.16 | ||
| Q1 24 | $-0.04 | $-0.25 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $7.1M | $228.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $908.9M | $275.7M |
| Total Assets | $1.7B | $311.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $228.1M | ||
| Q3 25 | $7.1M | $227.5M | ||
| Q2 25 | $4.8M | $227.5M | ||
| Q1 25 | $6.4M | $229.3M | ||
| Q4 24 | $6.1M | $237.2M | ||
| Q3 24 | $4.8M | $237.1M | ||
| Q2 24 | $5.6M | $233.3M | ||
| Q1 24 | $4.2M | $125.4M |
| Q4 25 | — | $275.7M | ||
| Q3 25 | $908.9M | $276.0M | ||
| Q2 25 | $1.0B | $278.0M | ||
| Q1 25 | $1.1B | $279.3M | ||
| Q4 24 | $1.1B | $281.2M | ||
| Q3 24 | $1.1B | $277.3M | ||
| Q2 24 | $1.1B | $275.2M | ||
| Q1 24 | $1.1B | $163.9M |
| Q4 25 | — | $311.8M | ||
| Q3 25 | $1.7B | $308.5M | ||
| Q2 25 | $1.8B | $309.0M | ||
| Q1 25 | $1.8B | $313.0M | ||
| Q4 24 | $1.8B | $318.6M | ||
| Q3 24 | $1.9B | $310.5M | ||
| Q2 24 | $1.9B | $305.5M | ||
| Q1 24 | $1.9B | $183.2M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $15.9M | $-1.1M |
| Free Cash FlowOCF − Capex | $7.2M | $-2.3M |
| FCF MarginFCF / Revenue | 11.6% | -6.9% |
| Capex IntensityCapex / Revenue | 14.0% | 3.5% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $86.7M | $-19.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-1.1M | ||
| Q3 25 | $15.9M | $-1.2M | ||
| Q2 25 | $29.8M | $-4.4M | ||
| Q1 25 | $16.2M | $-8.8M | ||
| Q4 24 | $95.2M | $-4.3M | ||
| Q3 24 | $20.7M | $650.0K | ||
| Q2 24 | $28.9M | $-4.0M | ||
| Q1 24 | $21.2M | $-9.3M |
| Q4 25 | — | $-2.3M | ||
| Q3 25 | $7.2M | $-1.8M | ||
| Q2 25 | $21.1M | $-5.9M | ||
| Q1 25 | $10.5M | $-9.4M | ||
| Q4 24 | $47.9M | $-5.1M | ||
| Q3 24 | $8.8M | $-453.0K | ||
| Q2 24 | $21.0M | $-5.5M | ||
| Q1 24 | $7.6M | $-11.3M |
| Q4 25 | — | -6.9% | ||
| Q3 25 | 11.6% | -5.8% | ||
| Q2 25 | 34.1% | -17.6% | ||
| Q1 25 | 17.1% | -24.8% | ||
| Q4 24 | 78.1% | -12.7% | ||
| Q3 24 | 14.4% | -1.3% | ||
| Q2 24 | 34.9% | -15.9% | ||
| Q1 24 | 12.8% | -38.2% |
| Q4 25 | — | 3.5% | ||
| Q3 25 | 14.0% | 1.9% | ||
| Q2 25 | 14.0% | 4.6% | ||
| Q1 25 | 9.2% | 1.5% | ||
| Q4 24 | 77.4% | 2.1% | ||
| Q3 24 | 19.4% | 3.1% | ||
| Q2 24 | 13.1% | 4.4% | ||
| Q1 24 | 22.9% | 6.7% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ELME
| Residential Segment | $57.7M | 93% |
| Other | $4.4M | 7% |
RXST
| Rxlal | $28.2M | 86% |
| LDD | $3.0M | 9% |
| Service Warranty Service Contracts And Accessories | $1.5M | 4% |
